Does the media refer more to VTGN or HOWL?

In the previous week, Werewolf Therapeutics had 1 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 3 mentions for Werewolf Therapeutics and 2 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 1.28 beat Werewolf Therapeutics' score of 1.20 indicating that VistaGen Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VistaGen Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TVGN or VTGN?

In the previous week, Tevogen Bio had 1 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 3 mentions for Tevogen Bio and 2 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 1.28 beat Tevogen Bio's score of 0.45 indicating that VistaGen Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tevogen Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VistaGen Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ATNM or VTGN?

In the previous week, VistaGen Therapeutics had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for VistaGen Therapeutics and 1 mentions for Actinium Pharmaceuticals. VistaGen Therapeutics' average media sentiment score of 1.28 beat Actinium Pharmaceuticals' score of 0.75 indicating that VistaGen Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VistaGen Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

VistaGen Therapeutics (VTGN) Competitors

$0.24 -0.01 (-4.10%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.24 0.00 (-0.04%)

As of 10/9/2026 07:52 PM Eastern

Compare

VTGN vs. HOWL, TVGN, MGX, EDSA, and ATNM

Should you buy VistaGen Therapeutics stock or one of its competitors? VistaGen Therapeutics's main competitors and comparable companies include Werewolf Therapeutics (HOWL), Tevogen Bio (TVGN), Metagenomi (MGX), Edesa Biotech (EDSA), and Actinium Pharmaceuticals (ATNM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does VistaGen Therapeutics compare to Werewolf Therapeutics?

VistaGen Therapeutics (NASDAQ:VTGN) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

VistaGen Therapeutics has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

Werewolf Therapeutics has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -2,702.64%. VistaGen Therapeutics' return on equity of -152.59% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%
Werewolf Therapeutics	N/A	-166.99%	-59.88%

Werewolf Therapeutics has higher revenue and earnings than VistaGen Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	8.25	-$69.68M	-$1.66	N/A
Werewolf Therapeutics	$1.88M	25.32	-$60.82M	-$0.76	N/A

In the previous week, Werewolf Therapeutics had 1 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 3 mentions for Werewolf Therapeutics and 2 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 1.28 beat Werewolf Therapeutics' score of 1.20 indicating that VistaGen Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VistaGen Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Werewolf Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

VistaGen Therapeutics currently has a consensus target price of $0.95, indicating a potential upside of 302.37%. Werewolf Therapeutics has a consensus target price of $4.00, indicating a potential upside of 308.33%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Werewolf Therapeutics is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Werewolf Therapeutics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Werewolf Therapeutics beats VistaGen Therapeutics on 13 of the 17 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

Tevogen Bio has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

Tevogen Bio has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -2,702.64%. Tevogen Bio's return on equity of 0.00% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-468.32%
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%

Tevogen Bio presently has a consensus target price of $100.00, indicating a potential upside of 1,374.93%. VistaGen Therapeutics has a consensus target price of $0.95, indicating a potential upside of 302.37%. Given Tevogen Bio's higher possible upside, analysts clearly believe Tevogen Bio is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Tevogen Bio had 1 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 3 mentions for Tevogen Bio and 2 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 1.28 beat Tevogen Bio's score of 0.45 indicating that VistaGen Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tevogen Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VistaGen Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tevogen Bio has higher earnings, but lower revenue than VistaGen Therapeutics. Tevogen Bio is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A
VistaGen Therapeutics	$1.27M	8.25	-$69.68M	-$1.66	N/A

78.4% of VistaGen Therapeutics shares are held by institutional investors. 65.6% of Tevogen Bio shares are held by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

VistaGen Therapeutics beats Tevogen Bio on 8 of the 14 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

In the previous week, VistaGen Therapeutics had 1 more articles in the media than Metagenomi. MarketBeat recorded 2 mentions for VistaGen Therapeutics and 1 mentions for Metagenomi. VistaGen Therapeutics' average media sentiment score of 1.28 beat Metagenomi's score of 0.91 indicating that VistaGen Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Metagenomi	Positive
VistaGen Therapeutics	Positive

78.4% of VistaGen Therapeutics shares are held by institutional investors. 12.5% of Metagenomi shares are held by insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

VistaGen Therapeutics has lower revenue, but higher earnings than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.50	-$87.87M	-$2.49	N/A
VistaGen Therapeutics	$1.27M	8.25	-$69.68M	-$1.66	N/A

Metagenomi has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

Metagenomi has a net margin of -384.61% compared to VistaGen Therapeutics' net margin of -2,702.64%. Metagenomi's return on equity of -63.65% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-63.65%	-44.52%
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%

Metagenomi currently has a consensus price target of $6.00, suggesting a potential upside of 500.00%. VistaGen Therapeutics has a consensus price target of $0.95, suggesting a potential upside of 302.37%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Metagenomi beats VistaGen Therapeutics on 10 of the 17 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Edesa Biotech?

VistaGen Therapeutics (NASDAQ:VTGN) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Edesa Biotech has lower revenue, but higher earnings than VistaGen Therapeutics. Edesa Biotech is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	8.25	-$69.68M	-$1.66	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A

VistaGen Therapeutics has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

VistaGen Therapeutics presently has a consensus price target of $0.95, indicating a potential upside of 302.37%. Edesa Biotech has a consensus price target of $5.00, indicating a potential upside of 42.45%. Given VistaGen Therapeutics' higher possible upside, research analysts clearly believe VistaGen Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by company insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Edesa Biotech has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -2,702.64%. VistaGen Therapeutics' return on equity of -152.59% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%
Edesa Biotech	N/A	-560.22%	-105.74%

In the previous week, VistaGen Therapeutics had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 2 mentions for VistaGen Therapeutics and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 1.79 beat VistaGen Therapeutics' score of 1.28 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
VistaGen Therapeutics	Positive
Edesa Biotech	Very Positive

Summary

Edesa Biotech beats VistaGen Therapeutics on 9 of the 16 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Actinium Pharmaceuticals currently has a consensus price target of $5.00, indicating a potential upside of 354.55%. VistaGen Therapeutics has a consensus price target of $0.95, indicating a potential upside of 302.37%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Actinium Pharmaceuticals is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, VistaGen Therapeutics had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for VistaGen Therapeutics and 1 mentions for Actinium Pharmaceuticals. VistaGen Therapeutics' average media sentiment score of 1.28 beat Actinium Pharmaceuticals' score of 0.75 indicating that VistaGen Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VistaGen Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Actinium Pharmaceuticals has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -2,702.64%. Actinium Pharmaceuticals' return on equity of -100.85% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%

Actinium Pharmaceuticals has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

Actinium Pharmaceuticals has higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$35.09M	0.99	-$48.82M	$0.36	3.06
VistaGen Therapeutics	$1.27M	8.25	-$69.68M	-$1.66	N/A

Summary

Actinium Pharmaceuticals beats VistaGen Therapeutics on 9 of the 16 factors compared between the two stocks.

Get VistaGen Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VTGN vs. The Competition

Export

Metric	VistaGen Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.48M	$3.93B	$7.25B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	-0.14	13.55	274.99	26.14
Price / Sales	8.25	1,209.42	582.85	87.88
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	0.26	17.17	11.22	6.33
Net Income	-$69.68M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-15.98%	-1.34%	-0.89%	-1.40%
1 Month Performance	-1.21%	-8.45%	-4.42%	-3.47%
1 Year Performance	-94.14%	14.02%	7.03%	1.18%

VistaGen Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VTGN VistaGen Therapeutics	2.253 of 5 stars	$0.24 -4.1%	$0.95 +302.4%	-94.4%	$10.48M	$1.27M	N/A	41	Positive News Gap Down
HOWL Werewolf Therapeutics	2.6967 of 5 stars	$0.93 -0.5%	$4.00 +332.4%	-45.0%	$44.96M	$1.88M	N/A	14	News Coverage Positive News Gap Up
TVGN Tevogen Bio	1.4516 of 5 stars	$6.87 +4.1%	$100.00 +1,355.8%	-81.6%	$44.40M	N/A	N/A	3	News Coverage
MGX Metagenomi	3.8316 of 5 stars	$1.07 +2.9%	$6.00 +460.7%	-68.1%	$40.50M	$13.56M	N/A	113
EDSA Edesa Biotech	2.9763 of 5 stars	$3.91 +1.2%	$5.00 +28.0%	+34.5%	$37.65M	N/A	N/A	17	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VTGN) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VistaGen Therapeutics (VTGN) Competitors

VTGN vs. HOWL, TVGN, MGX, EDSA, and ATNM

How does VistaGen Therapeutics compare to Werewolf Therapeutics?

Summary

How does VistaGen Therapeutics compare to Tevogen Bio?

Summary

How does VistaGen Therapeutics compare to Metagenomi?

Summary

How does VistaGen Therapeutics compare to Edesa Biotech?

Summary

How does VistaGen Therapeutics compare to Actinium Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN vs. The Competition

VistaGen Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

VistaGen Therapeutics (VTGN) Competitors

VTGN vs. HOWL, TVGN, MGX, EDSA, and ATNM

How does VistaGen Therapeutics compare to Werewolf Therapeutics?

Which has more volatility & risk, VTGN or HOWL?

Is VTGN or HOWL more profitable?

Which has stronger valuation & earnings, VTGN or HOWL?

Does the media refer more to VTGN or HOWL?

Do analysts rate VTGN or HOWL?

Do institutionals and insiders believe in VTGN or HOWL?

Summary

How does VistaGen Therapeutics compare to Tevogen Bio?

Which has more volatility and risk, TVGN or VTGN?

Is TVGN or VTGN more profitable?

Do analysts rate TVGN or VTGN?

Does the media favor TVGN or VTGN?

Which has better valuation & earnings, TVGN or VTGN?

Do institutionals & insiders believe in TVGN or VTGN?

Summary

How does VistaGen Therapeutics compare to Metagenomi?

Does the media favor MGX or VTGN?

Do institutionals and insiders have more ownership in MGX or VTGN?

Which has preferable earnings and valuation, MGX or VTGN?

Which has more volatility & risk, MGX or VTGN?

Is MGX or VTGN more profitable?

Do analysts recommend MGX or VTGN?

Summary

How does VistaGen Therapeutics compare to Edesa Biotech?

Which has stronger earnings & valuation, VTGN or EDSA?

Which has more risk and volatility, VTGN or EDSA?

Do analysts recommend VTGN or EDSA?

Do insiders and institutionals believe in VTGN or EDSA?

Is VTGN or EDSA more profitable?

Does the media favor VTGN or EDSA?

Summary

How does VistaGen Therapeutics compare to Actinium Pharmaceuticals?

Do institutionals and insiders believe in ATNM or VTGN?

Do analysts recommend ATNM or VTGN?

Does the media prefer ATNM or VTGN?

Is ATNM or VTGN more profitable?

Which has more volatility & risk, ATNM or VTGN?

Which has stronger valuation and earnings, ATNM or VTGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN vs. The Competition

VistaGen Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools